Further investigation into how SLC7A11 affects fibrosis at the cellular, organ, and immune system levels is crucial for developing targeted therapies, particularly for liver fibrosis, and advancing our understanding of its potential as a therapeutic target in fibrotic diseases. This evidence concerns the gene SLC7A11 and Hepatic fibrosis.